Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas and Teijin Pharma Extend Febuxostat Partnership To China

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Astellas will work with Teijin Pharma to market the latter's febuxostat in China and Hong Kong, expanding their partnership on the first new gout drug in 40 years

You may also be interested in...



Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded

TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China

Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded

TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China

Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded

Astellas outlines its growth strategy, offering ways the company plans to overcome the sales loss of U.S. patent expiries for blockbusters Prograf (tacrolimus) and Harnal (tamsulosin).

Related Content

UsernamePublicRestriction

Register

SC074490

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel